| | | |
Bladder |
NCT06305767 V940-005, V940-005,U1111-1292-1952,2023-505658-17-00,INTerpath-005 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | Dr. Girish Kulkarni | Bladder |
NCT05327647 MP-20-2022-6318 | A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer | Dr. Girish Kulkarni | Bladder |
NCT06111235 PIVOT-006 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Dr. Girish Kulkarni | Bladder |
NCT05014139 SGN22E-004, EV-104,C5701004,2023-503388-40-00 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | Dr. Girish Kulkarni | Bladder |
NCT04165317 B8011006, CREST,2023-509089-39-00 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Dr. Girish Kulkarni | Bladder |
NCT05714202 CR109223, 17000139BLC3002,2020-004506-64,2023-507187-39-00 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | Dr. Girish Kulkarni | Bladder |
NCT05911295 SGNDV-001, C5731001,2022-501105-12-00 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Dr. Srikala Sridhar | Bladder |
NCT03711032 3475-676, MK-3475-676,194713,jRCT2031200390,2018-001967-22 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Dr. Girish Kulkarni | Bladder |
NCT05037279 VRT-BCG-01 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) | Dr. Girish Kulkarni | Bladder |
NCT03945162 Ruvidar® (TLD-1433) NMIBC PDT | Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | Dr. Girish Kulkarni | Bladder |
NCT04752722 EG-70-101 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Dr. Girish Kulkarni | Bladder |
NCT05951179 TARA-002-101-Ph2 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Dr. Girish Kulkarni | Bladder |
Kidney / Renal |
NCT04011891 18-5885 | Comparison of OpeN VErsus RoboTic Partial Nephrectomy | Dr. Robert Hamilton | Kidney / Renal |
NCT03747133 18-5481 | SABR for Renal Tumors | Dr. Rachel Glicksman | Kidney / Renal |
NCT04987203 AV-951-20-304 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | Dr. Srikala Sridhar | Kidney / Renal |
NCT05327686 NRG-GU012, NCI-2022-02189,NRG-GU012,NRG-GU012,U10CA180868 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Dr. Andrew McPartlin | Kidney / Renal |
Multiple Sites |
NCT03067181 AGCT1531, NCI-2017-00178,AGCT1531,AGCT1531,AGCT1531,U10CA180886 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Dr. Robert Hamilton | Multiple Sites |
NCT04223856 SGN22E-003, 2019-004542-15,MK-3475-A39,KEYNOTE KN-A39,jRCT2031200284,CTR20220974 | Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | Dr. Srikala Sridhar | Multiple Sites |
Other |
NCT05562830 3475-04A, MK-3475-04A,2023-506384-34-00,U1111-1293-7548,2020-004544-28 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | Dr. Srikala Sridhar | Other |
NCT06124976 H23-02476 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | Dr. Girish Kulkarni | Other |